AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$ZBH

Zimmer Biomet beats Q3 estimates, raises guidance

Zimmer Biomet (ZBH) reported Q3 adjusted EPS of $1.90, beating estimates by $0.02, with revenue of $2.06B, up 3.1% YoY. The company raised its 2026 adjusted EPS guidance to $8.50-$8.60. Shares rose 1.5% post-results. Key segments like Hips and Technology & Data showed strong growth, while Knees declined.

Original reporting
investing.com
Published Nov 4, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZBH
Bullish
high confidence
Mentioned
$ZBH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZBHBullishHigh
01

Why it matters

The earnings beat and guidance raise provide fresh, material information that can influence short‑term trading decisions.

02

Market read

The report is a primary earnings disclosure for a large-cap U.S. med‑tech firm, offering actionable insight for traders.

03

What to watch

Potential headwinds from supply chain constraints in orthopedic implants could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Zimmer Biomet is a leading orthopedics and surgical device maker; its earnings beat and guidance raise are key data points for the sector.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Zimmer Biomet reported Q3 earnings beat and raised full-year 2026 EPS guidance to $8.50-$8.60.

Expected impact

likely modest upside as investors price in higher earnings expectations

Evidence & confidence

The beat and guidance lift are fresh primary disclosures for a large-cap med‑tech company, driving short‑term buying pressure.

Market effects

Sector

May boost sentiment for the broader medical device sector.

Regional

U.S. med‑tech stocks could see slight gains.

Global

Limited to investors tracking U.S. healthcare equities.

Counterpoint

What could challenge this read

The modest 1.5% price move suggests the beat was already priced in; caution on over‑optimism.

Key entities

  • company
    Zimmer Biomet Holdings Inc.

    Medical technology company reporting Q3 results.

Read at source← All news

StoryZimmer Biomet posts Q3 2026 results and lifts full‑year outlook

Also covered by

5 outlets

Related articles

NOV 4
$ZBHHighAI 8/10

Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

rttnews.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet (NYSE:ZBH) exceeds Q3 2026 expectations

Zimmer Biomet reported Q3 2026 revenue of $2.06B, beating estimates by 1.1% and growing 3.1% YoY. Adjusted EPS was $1.90, a 1% beat. Management raised full-year adjusted EPS guidance to $8.55. Operating margin declined to 14.9%, while free cash flow margin increased to 18.1%. Constant currency revenue grew 3.7% YoY, down from 8.6% last quarter.

finance.yahoo.com1 min
NOV 4
$ZBHHighAI 8/10

Zimmer: Q3 Earnings Snapshot

Zimmer Biomet Holdings Inc. (ZBH) reported Q3 profit of $191.6M, or $1 per share, beating estimates. Adjusted EPS was $1.90, and revenue was $2.06B, also exceeding forecasts. The company expects full-year EPS of $8.50-$8.60. (Zacks)

finance.yahoo.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet Q3 Sales Rise 3.1%; Raises 2026 Growth Guidance

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% YoY. EPS was $1.00, adjusted EPS was $1.90. The company raised its 2026 guidance, expecting 3.0%–3.5% revenue growth and adjusted EPS of $8.50–$8.60. Strong performance in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical franchises. Extended agreement with THINK Surgical and opened a new training facility.

tradingview.com1 min